Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke: A Multicenter, Randomized, Parallel-controlled Clinical Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Ischemic Stroke
- Sponsor
- Yi Yang
- Enrollment
- 2210
- Locations
- 1
- Primary Endpoint
- Proportion of patients with modified Rankin Scale (mRS) Score 0-2.
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.
Detailed Description
In this study, 2210 cases of ischemic stroke in 72 hours were included in 10 centers in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days. Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning in treating acute ischemic stroke.
Investigators
Yi Yang
Associated Dean of First Hospital of Jilin University
The First Hospital of Jilin University
Eligibility Criteria
Inclusion Criteria
- •Age≥18 years, regardless of sex.
- •Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 72 hours of stroke onset.
- •Baseline NIHSS ≥ 4, ≤
- •Baseline mRS ≤ 2;
- •Signed and dated informed consent is obtained.
Exclusion Criteria
- •Patients who undergo thrombolytic therapy or endovascular treatment.
- •The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture, or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc.
- •Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumors,s and other diseases involving the brain.
- •Pregnant or lactating women.
- •Previous remote ischemic conditioning therapy or similar treatment.
- •Severe hepatic and renal dysfunction.
- •Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons.
- •Unwilling to be followed up or treated for poor compliance.
- •He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission.
- •Other conditions that the researchers think are not suitable for the group.
Outcomes
Primary Outcomes
Proportion of patients with modified Rankin Scale (mRS) Score 0-2.
Time Frame: 3 months
Proportion of patients with modified Rankin Scale (mRS) Score 0-2. Ranged from 0 to 6, a low value represents a better outcome.
Secondary Outcomes
- National Institute of Health stroke scale (NIHSS) at 7 days, 30±3 days, 90±3 days from onset.(7days, 30±3 days, 90±3 days)
- modified Rankin Scale (mRS) Score at 7 days, 30±3 days, 90±3 days from onset.(7days, 30±3 days, 90±3 days)
- Barthel Index (BI) at 7 days, 30±3 days, 90±3 days from onset.(7days, 30±3 days, 90±3 days)
- Proportion of patients with hemorrhagic transformation during hospitalization.(7 days)
- Frequency of adverse events during follow-up.(90 days)